Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
A better understanding of the roles of the adaptive and innate immune systems in the
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
NWCJ van de Donk, A Chari, MV Mateos - The Lancet Haematology, 2024 - thelancet.com
Off-the-shelf T-cell-redirecting bispecific antibodies targeting BCMA, GPRC5D, and FcRH5
have high activity in multiple myeloma with a manageable toxicity profile. However, not all …
have high activity in multiple myeloma with a manageable toxicity profile. However, not all …
A comeback for checkpoint inhibition in multiple myeloma
M Merz - Nature Cancer, 2024 - nature.com
Early trials of immune checkpoint inhibitors (ICIs) in multiple myeloma (MM) showed
increased mortality, halting their development. A study now reports promising results and …
increased mortality, halting their development. A study now reports promising results and …
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement
MR Heerma van Voss, RJ Molenaar… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction T-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation
antigen (BCMA) or G-protein–coupled receptor class C group 5 member D (GPRC5D), are …
antigen (BCMA) or G-protein–coupled receptor class C group 5 member D (GPRC5D), are …
Forimtamig, a novel GPRC5D targeting T cell bispecific antibody with 2+ 1 format for the treatment of multiple myeloma
J Eckmann, T Fauti, M Biehl, A Zabaleta, L Blanco… - Blood, 2024 - Elsevier
Despite several approved therapies, multiple myeloma (MM) remains an incurable disease
with high unmet medical need.“Off-the-shelf” T-cell bispecific antibodies (TCBs) targeting …
with high unmet medical need.“Off-the-shelf” T-cell bispecific antibodies (TCBs) targeting …
T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment
T cell–redirecting bispecific antibodies (BsAb) induce significant responses in heavily
pretreated multiple myeloma. BsAbs are currently administered in a dose-dense manner …
pretreated multiple myeloma. BsAbs are currently administered in a dose-dense manner …
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma
Establishing a strategy for sequencing of T cell–redirecting therapies for relapsed/refractory
multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical …
multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical …
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
Recent advancements in multiple myeloma (MM) treatment—including immunomodulatory
drugs, proteasome inhibitors, monoclonal antibodies, and T cell–redirecting therapies like …
drugs, proteasome inhibitors, monoclonal antibodies, and T cell–redirecting therapies like …
[HTML][HTML] Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?
Although the prognosis of patients with multiple myeloma (MM) has been significantly
improved by the introduction of proteasome inhibitors, immunomodulatory drugs and …
improved by the introduction of proteasome inhibitors, immunomodulatory drugs and …
[HTML][HTML] Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives: Clinical Lymphoma …
JM Waldschmidt, L Rasche, KM Kortüm… - … Lymphoma Myeloma and …, 2024 - Elsevier
Despite significant advancements, multiple myeloma (MM) remains incurable, and there is
still a pressing need for new therapeutic strategies with highly selective mechanisms of …
still a pressing need for new therapeutic strategies with highly selective mechanisms of …